Author: Zwaenepoel, Bert; Dhont, Sebastiaan; Schaubroeck, Hannah; Gevaert, Sofie
Title: The use of cardiac troponins and B-type natriuretic peptide in COVID-19 Cord-id: sl8y5pj9 Document date: 2021_8_30
ID: sl8y5pj9
Snippet: Coronavirus disease 2019 (COVID-19) is still challenging health care systems worldwide. Over time, it has become clear that respiratory disease is not the only important entity as critically ill patients are also more prone to develop complications, such as acute cardiac injury. Despite extensive research, the mainstay of treatment still relies on supportive care and targeted therapy of these complications. The development of a prognostic model which helps clinicians to diverge patients to an ap
Document: Coronavirus disease 2019 (COVID-19) is still challenging health care systems worldwide. Over time, it has become clear that respiratory disease is not the only important entity as critically ill patients are also more prone to develop complications, such as acute cardiac injury. Despite extensive research, the mainstay of treatment still relies on supportive care and targeted therapy of these complications. The development of a prognostic model which helps clinicians to diverge patients to an appropriate level of care is thus crucial. As a result, several prognostic markers have been studied in the past few months. Among them are the cardiac biomarkers, especially cardiac troponins T/I and brain natriuretic peptide, which seem to have important prognostic values as several reports have confirmed their strong association with adverse clinical outcomes and death. The use of these biomarkers as part of a prognostic tool could potentially result in more precise risk stratification of COVID-19 patients and divergence to an adequate level of care. However, several caveats persist causing international guidelines to still recommend in favour of a more conservative approach to cardiac biomarker testing for prognostic purposes.
Search related documents:
Co phrase search for related documents- acs coronary syndrome and acute acs coronary syndrome hospital admission: 1
- acs coronary syndrome and acute respiratory failure: 1, 2
- acs coronary syndrome and acute setting: 1, 2, 3, 4
- acs coronary syndrome and admission level: 1, 2
- acs coronary syndrome and admission reduction: 1, 2, 3
- acs coronary syndrome and lymphocyte count: 1
- acs hospital admission and acute acs coronary syndrome: 1, 2, 3
- acute acs coronary syndrome and admission level: 1, 2
- acute acs coronary syndrome and admission reduction: 1, 2, 3
- acute acs coronary syndrome and lymphocyte count: 1
- acute cardiac injury and admission level: 1, 2, 3, 4, 5
- acute cardiac injury and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute decompensation and admission level: 1
- acute decompensation and lymphocyte count: 1
- acute kidney injury and admission level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute kidney injury and admission reduction: 1
- acute kidney injury and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- acute respiratory failure and admission level: 1, 2, 3, 4, 5, 6, 7, 8
- acute respiratory failure and admission reduction: 1
Co phrase search for related documents, hyperlinks ordered by date